Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid.
Yanae M, Fujimoto S, Tane K, Tanioka M, Fujiwara K, Tsubaki M, Yamazoe Y, Morishima Y, Chiba Y, Takao S, Komoike Y, Tsurutani J, Nakagawa K, Nishida S.
Yanae M, et al. Among authors: fujimoto s.
J Bone Oncol. 2017 Aug 31;8:18-22. doi: 10.1016/j.jbo.2017.08.004. eCollection 2017 Sep.
J Bone Oncol. 2017.
PMID: 28884071
Free PMC article.